FIELD: medicine.
SUBSTANCE: invention refers to experimental medicine, namely to phthisiology and thoracic surgery. Immunosuppressant infliximab in dose of 10 mg/kg is introduced into a marginal ear vein in rabbits. One day later, soft tissues are incised to the pleura, after which a catheter is inserted into the pleural cavity, through which a suspension of Mycobacterium tuberculosis H37Rv strain in concentration of 106 microbial cells in 10 ml of physiological solution and 40 ml of air is introduced.
EFFECT: method makes it possible to reproduce tuberculosis pleura under experimental conditions using minimally invasive surgical approach, which in turn makes it possible to carry out lifetime monitoring of development and assessment of severity of specific inflammatory process from the moment of infection to euthanasia in a specific animal included in the study.
1 cl, 6 dwg, 1 ex
| Title | Year | Author | Number |
|---|---|---|---|
| METHOD FOR SIMULATING KIDNEY TUBERCULOSIS | 2021 |
|
RU2776130C1 |
| TEST MODIFICATION METHOD FOR IN VITRO DIAGNOSIS OF TUBERCULOUS PLEURISY | 2019 |
|
RU2708388C1 |
| METHOD OF MODELING COMBINED PATHOLOGY OF LUNG CARCINOMA AND TUBERCULOSIS | 2022 |
|
RU2800964C1 |
| METHOD FOR MODELING TUBERCULOSIS OF FEMALE GENITAL ORGANS | 2015 |
|
RU2600926C2 |
| METHOD OF TREATING PLEURAL EMPYEMA | 2017 |
|
RU2661090C1 |
| METHOD FOR INACTIVATION OF DRUG-SENSITIVE AND DRUG-RESISTANT STRAINS OF MYCOBACTERIUM TUBERCULOSIS IN EXPERIMENTAL CONDITIONS IN VITRO | 2018 |
|
RU2702646C1 |
| METHOD FOR LIMITED CHRONIC PLEURAL EMPYEMA SIMULATION | 2016 |
|
RU2636177C1 |
| MEDICINE FORMING CELLULAR IMMUNITY FOR MYCOBACTERIUM TUBERCULOSIS H37 Rv, METHOD OF PRODUCTION THEREOF (VERSIONS), RECOMBINANT STRAIN AND TUBERCULOSIS DIAGNOSTIC AGENT | 2007 |
|
RU2341288C1 |
| ANTI-TUBERCULOSIS DRUG BASED ON (Z)-3-(3,3-DIMETHYL-2-OXOBUTYLIDENE) -3,4-DIHYDRO-2H-1,4-BENZOXAZIN-2-ONE AND A METHOD FOR ITS SYNTHESIS | 2020 |
|
RU2748748C1 |
| COMBINED ANTITUBERCULOUS COMPOSITION | 2009 |
|
RU2413517C1 |
